Medical Cannabis for ADHD in the UK: What Patients Need to Know

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) is one of the most common neurodevelopmental conditions in the UK, affecting an estimated 2.5 million adults. Yet access to diagnosis and treatment remains severely limited — NHS waiting lists for adult ADHD assessment can stretch to three years or more in some regions. Against this backdrop, a growing number of UK patients are exploring medical cannabis as a complementary or alternative approach to managing their symptoms.

Since medical cannabis was legalised in the UK in November 2018, specialist clinicians have been able to prescribe cannabis-based medicinal products (CBMPs) for a wide range of conditions, including ADHD, when conventional treatments have proven inadequate. This guide explains what the evidence says, who may be eligible, and how to access a prescription in the UK.

What Does the Research Say?

The clinical evidence for medical cannabis in ADHD is still emerging, but early findings are encouraging. A 2023 analysis published in the journal Frontiers in Psychiatry, drawing on data from the UK Medical Cannabis Registry (UKMCR), found that patients with ADHD who were prescribed CBMPs reported statistically significant improvements in anxiety, sleep quality, and overall quality of life over a six-month period.

The UKMCR study, led by researchers at Imperial College London, assessed 68 adult patients with ADHD. At the six-month follow-up, participants showed meaningful reductions in self-reported ADHD symptom severity, with particular improvements in emotional dysregulation and sleep disturbance — two of the most debilitating aspects of adult ADHD.

The proposed mechanism relates to the endocannabinoid system (ECS), which plays a regulatory role in dopamine and noradrenaline signalling — the same neurotransmitter pathways targeted by conventional ADHD medications such as methylphenidate (Ritalin) and lisdexamfetamine (Vyvanse). Cannabinoids, particularly CBD and low-dose THC, may modulate these pathways, potentially reducing hyperactivity, impulsivity, and emotional dysregulation.

It is important to note that the evidence base is not yet at the level of randomised controlled trials. Most data comes from observational studies and patient registries. The NHS does not currently recommend medical cannabis as a first-line treatment for ADHD.

Who May Be Eligible in the UK?

Under UK prescribing guidelines, medical cannabis for ADHD is typically considered when:

• The patient has a confirmed ADHD diagnosis from a qualified clinician

• At least two conventional ADHD medications have been tried and have either failed to provide adequate relief or caused intolerable side effects

• The prescribing specialist (usually a psychiatrist or neurologist) is satisfied that the potential benefits outweigh the risks

The ADHD medication shortage that began in 2023 and continued into 2025 — affecting supplies of methylphenidate, lisdexamfetamine, and atomoxetine — has led many patients to seek alternative options, and some UK cannabis clinics have reported a significant increase in ADHD referrals during this period.

What Products Are Typically Prescribed?

For ADHD, UK specialists most commonly prescribe:

• CBD-dominant oils or capsules — for patients where anxiety and emotional dysregulation are the primary concerns, and where THC is contraindicated

• Balanced THC:CBD products — for patients with sleep disturbance alongside ADHD symptoms

• Low-dose THC flower for vaporisation — for patients who have not responded to oil-based formulations

The specific product, dose, and titration schedule will be determined by the prescribing clinician based on the patient's individual profile, medical history, and symptom pattern.

How to Access a Prescription

The process for obtaining a medical cannabis prescription for ADHD in the UK typically involves the following steps:

1. Initial consultation — A specialist clinician (usually via a private medical cannabis clinic) reviews your medical history, existing ADHD diagnosis, and previous treatment history. 2. Eligibility assessment — The clinician determines whether you meet the criteria for a CBPM prescription. 3. Prescription and pharmacy — If approved, the prescription is sent to a licensed pharmacy. Products are typically delivered directly to your home. 4. Follow-up appointments — Regular check-ins (usually monthly) allow the clinician to monitor your response and adjust the prescription as needed.

CPGUK works with patients to help them understand their options and navigate the process of accessing medical cannabis in the UK. If you have ADHD and have not found adequate relief from conventional treatments, our team can provide free, confidential guidance.

Important Considerations

Medical cannabis is not suitable for everyone with ADHD. It is generally not recommended for:

• Patients under 18 years of age (paediatric prescribing is subject to much stricter criteria)

• Patients with a personal or family history of psychosis or schizophrenia

• Pregnant or breastfeeding women

• Patients with certain cardiovascular conditions

The cost of private medical cannabis prescriptions in the UK typically ranges from £150 to £400 per month, depending on the product and dose. NHS prescriptions for ADHD-related CBMPs remain extremely rare.

Conclusion

Medical cannabis represents a promising option for adults with ADHD who have not found adequate relief from conventional treatments. The evidence base is growing, UK prescribing is legal and accessible through private specialist clinics, and patient-reported outcomes from the UK Medical Cannabis Registry are broadly positive. If you are considering this option, CPGUK is here to help you understand the process and connect with appropriate clinical support.